← SynDRA
SYN2269225
SynDRA canonical compound SYN2269225 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | RIPK2 |
|---|
| Mechanism of action | ripk inhibitor |
|---|
| Indication | inflammatory bowel disease |
|---|
| Disease area | gastroenterology |
|---|
Cross-references
Synonyms
- RefChem:394757
- GSK2983559 free acid
- GSK2983559
- MFCD30489430
- RIP2-IN-3
- GSK2983559 (free acid)
- GSK2983559 (compound 3)
- RIPK2 inhibitor 3
- GSK-2983559 free acid
- GSK2983559, free acid
- orb1309600
- WJY2LV4368
- C21H23N4O7PS2
- SCHEMBL15578200
- SCHEMBL29372367
- SCHEMBL31500671
- GTPL10413
- GLXC-21340
- ENC96512
- EX-A3446
- BDBM50405272
- s8927
- AKOS030527989
- compound 3 [PMID: 31265286]
- GSK-2983559
- GSK2983559?
- Example 1 [WO2014043446A1]
- AC-36438
- HY-112038
- CS-0042468
- T11492
- F799042
- K9T
- SCHEMBL15578220
- 2DFS6M9JDJ
- GSK-2983559 hydrochloride
- BDBM50516678
Look up SYN2269225 in the interactive SynDRA portal →